Stockscreener 앱 받기
14.10
1.61%
-0.23
시간 외 거래:
14.13
0.03
+0.21%
Vor Biopharma Inc 주식(VOR)의 최신 뉴스
VOR Stock Price, Quote & Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
VOR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $31 - GuruFocus
H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co. - Moomoo
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Vor Biopharma Inc.Common Stock (NQ: VOR - FinancialContent
Venrock group holds capped 9.99% stake in VOR (VOR) via pre-funded warrants - Stock Titan
Verve Capital amends position; holds 9.3% of VOR (NASDAQ: VOR) - Stock Titan
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Moomoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely - Yahoo Finance
Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR - Moomoo
VOR Maintained by Wedbush -- Price Target Raised to $18.00 - GuruFocus
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma Inc. Q1 2026 Financial Results and Forward-Looking Statements – SEC 10-Q Report - Minichart
Vor Bio Q1 Net Loss Narrows - Moomoo
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss - marketscreener.com
Vor Biopharma Inc. 1Q 2026: Net loss $(219.6M), Diluted EPS $(5.11) — 10-Q Summary - TradingView
Vor Biopharma Q1 net loss widens - TradingView
Vor Biopharma (NASDAQ: VOR) Q1 2026 loss widens as telitacicept trials advance on $491.5M cash runway - Stock Titan
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
TradingKey - TradingKey
MSN Money - MSN
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade - MSN
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High - TipRanks
[EFFECT] Vor Biopharma Inc. SEC Filing - Stock Titan
Qiming entities report stakes in VOR BioPharma (NASDAQ: VOR) on Schedule 13G/A - Stock Titan
FMR LLC reports 1.54M-share stake in VOR Biopharma (NASDAQ: VOR) - Stock Titan
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Vor Bio hires get stock awards priced at $13.85 - Stock Titan
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April - MarketBeat
Vor Biopharma (NASDAQ: VOR) files resale registration for 5.34M shares - Stock Titan
Vor Biopharma (NASDAQ: VOR) plans virtual 2026 meeting and equity plan changes - Stock Titan
[ARS] Vor Biopharma Inc. SEC Filing - Stock Titan
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Vor Bio announces $75M private placement - MSN
Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares - MarketBeat
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m By Investing.com - Investing.com Australia
Ra capital healthcare fund sells 165,150 Vor Biopharma shares for $2.6m - Investing.com UK
0.98%
0.12%
자본화:
|
볼륨(24시간):